| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Interleukin-6 | 16 | 2019 | 198 | 4.160 |
Why?
|
| Keratinocytes | 9 | 2019 | 33 | 3.320 |
Why?
|
| Skin | 12 | 2020 | 152 | 2.930 |
Why?
|
| Dermatitis, Contact | 5 | 2019 | 7 | 2.480 |
Why?
|
| Irritants | 4 | 2019 | 7 | 2.410 |
Why?
|
| Receptors, Interleukin-6 | 5 | 2019 | 11 | 1.890 |
Why?
|
| Wound Healing | 7 | 2019 | 126 | 1.270 |
Why?
|
| Dermatitis, Irritant | 2 | 2019 | 2 | 0.990 |
Why?
|
| Fibroblasts | 5 | 2012 | 160 | 0.970 |
Why?
|
| Gene Expression Regulation | 7 | 2019 | 634 | 0.960 |
Why?
|
| Mice | 31 | 2020 | 4802 | 0.910 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2017 | 9 | 0.830 |
Why?
|
| Animals | 38 | 2020 | 10684 | 0.820 |
Why?
|
| Transforming Growth Factor beta | 3 | 2017 | 79 | 0.820 |
Why?
|
| Mice, Inbred C57BL | 22 | 2020 | 1653 | 0.790 |
Why?
|
| Epidermis | 2 | 2019 | 11 | 0.780 |
Why?
|
| Liver | 10 | 2012 | 471 | 0.740 |
Why?
|
| Alcohol Drinking | 7 | 2012 | 176 | 0.710 |
Why?
|
| Cytokines | 10 | 2019 | 451 | 0.690 |
Why?
|
| Petroleum Pollution | 1 | 2020 | 3 | 0.670 |
Why?
|
| Occupational Diseases | 1 | 2020 | 8 | 0.670 |
Why?
|
| Hydrocarbons | 5 | 2019 | 41 | 0.670 |
Why?
|
| Dermatitis | 1 | 2020 | 7 | 0.660 |
Why?
|
| Petroleum | 1 | 2020 | 34 | 0.650 |
Why?
|
| Water Pollutants, Chemical | 1 | 2020 | 55 | 0.640 |
Why?
|
| Inflammation | 4 | 2019 | 667 | 0.640 |
Why?
|
| Receptors, Interleukin | 1 | 2019 | 12 | 0.630 |
Why?
|
| Myeloid Cells | 1 | 2019 | 27 | 0.610 |
Why?
|
| Mice, Knockout | 11 | 2019 | 874 | 0.600 |
Why?
|
| Hyperglycemia | 1 | 2019 | 78 | 0.570 |
Why?
|
| Benzalkonium Compounds | 4 | 2019 | 9 | 0.550 |
Why?
|
| Gene Expression | 3 | 2018 | 417 | 0.530 |
Why?
|
| Phenotype | 1 | 2019 | 685 | 0.510 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 465 | 0.490 |
Why?
|
| Chemokines | 5 | 2019 | 74 | 0.480 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2012 | 251 | 0.480 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 2 | 2012 | 9 | 0.430 |
Why?
|
| I-kappa B Proteins | 2 | 2012 | 11 | 0.390 |
Why?
|
| Disease Models, Animal | 6 | 2019 | 1507 | 0.390 |
Why?
|
| Cells, Cultured | 10 | 2019 | 1022 | 0.380 |
Why?
|
| I-kappa B Kinase | 1 | 2012 | 8 | 0.380 |
Why?
|
| Killer Cells, Natural | 8 | 2000 | 65 | 0.380 |
Why?
|
| Dermis | 1 | 2012 | 4 | 0.370 |
Why?
|
| Estrogens | 1 | 2012 | 56 | 0.370 |
Why?
|
| Macrophages | 3 | 2012 | 305 | 0.360 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2012 | 40 | 0.350 |
Why?
|
| Estradiol | 1 | 2012 | 176 | 0.350 |
Why?
|
| Suppressor of Cytokine Signaling 3 Protein | 3 | 2019 | 6 | 0.310 |
Why?
|
| Ethanol | 8 | 2012 | 125 | 0.300 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 278 | 0.300 |
Why?
|
| RNA, Small Interfering | 2 | 2024 | 198 | 0.280 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 11 | 0.270 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2007 | 9 | 0.270 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2007 | 16 | 0.260 |
Why?
|
| Cell Movement | 3 | 2007 | 376 | 0.250 |
Why?
|
| Male | 12 | 2020 | 13921 | 0.250 |
Why?
|
| Actins | 1 | 2006 | 99 | 0.240 |
Why?
|
| Flow Cytometry | 4 | 2024 | 292 | 0.230 |
Why?
|
| Alcoholism | 4 | 1995 | 121 | 0.230 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 1995 | 30 | 0.230 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 465 | 0.230 |
Why?
|
| RNA, Messenger | 8 | 2012 | 668 | 0.220 |
Why?
|
| Lentivirus | 1 | 2024 | 16 | 0.210 |
Why?
|
| Gene Knockdown Techniques | 1 | 2024 | 134 | 0.210 |
Why?
|
| Phosphorylation | 4 | 2012 | 585 | 0.200 |
Why?
|
| Animals, Newborn | 2 | 2017 | 182 | 0.200 |
Why?
|
| Sex Characteristics | 1 | 2004 | 173 | 0.200 |
Why?
|
| Blotting, Western | 1 | 2024 | 515 | 0.190 |
Why?
|
| Rats | 7 | 2012 | 1588 | 0.190 |
Why?
|
| STAT3 Transcription Factor | 3 | 2012 | 97 | 0.180 |
Why?
|
| Interleukin-2 | 3 | 1996 | 35 | 0.180 |
Why?
|
| Adjuvants, Immunologic | 1 | 2001 | 68 | 0.170 |
Why?
|
| Transcription, Genetic | 3 | 2018 | 404 | 0.170 |
Why?
|
| Skin Irritancy Tests | 1 | 2020 | 4 | 0.170 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 150 | 0.160 |
Why?
|
| Occupational Exposure | 1 | 2020 | 28 | 0.160 |
Why?
|
| Liver Regeneration | 1 | 2000 | 6 | 0.160 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2000 | 7 | 0.160 |
Why?
|
| Neutrophils | 3 | 2019 | 183 | 0.160 |
Why?
|
| Models, Animal | 1 | 2020 | 130 | 0.160 |
Why?
|
| Female | 15 | 2020 | 15624 | 0.160 |
Why?
|
| Rats, Wistar | 3 | 2012 | 153 | 0.150 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2012 | 44 | 0.150 |
Why?
|
| Streptozocin | 1 | 2019 | 11 | 0.150 |
Why?
|
| CD11 Antigens | 1 | 2019 | 3 | 0.150 |
Why?
|
| Genotype | 1 | 2020 | 461 | 0.150 |
Why?
|
| Signal Transduction | 2 | 2019 | 1469 | 0.150 |
Why?
|
| Genetic Variation | 1 | 2020 | 245 | 0.150 |
Why?
|
| Cell Division | 6 | 2004 | 154 | 0.150 |
Why?
|
| Coal | 1 | 2018 | 11 | 0.150 |
Why?
|
| Immunity | 1 | 2018 | 27 | 0.140 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2019 | 98 | 0.140 |
Why?
|
| Kidney | 2 | 2018 | 289 | 0.140 |
Why?
|
| Transforming Growth Factors | 1 | 2017 | 2 | 0.140 |
Why?
|
| Smad7 Protein | 1 | 2017 | 6 | 0.140 |
Why?
|
| Psoriasis | 1 | 2017 | 7 | 0.140 |
Why?
|
| Monocytes | 1 | 2019 | 135 | 0.140 |
Why?
|
| Glucose | 1 | 2019 | 209 | 0.130 |
Why?
|
| Smad Proteins | 1 | 2017 | 18 | 0.130 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 36 | 0.130 |
Why?
|
| Humans | 10 | 2024 | 28851 | 0.120 |
Why?
|
| Biomarkers | 1 | 2019 | 776 | 0.120 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1995 | 1 | 0.120 |
Why?
|
| Lymphocyte Activation | 1 | 1996 | 210 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 344 | 0.110 |
Why?
|
| Cell Proliferation | 1 | 2017 | 824 | 0.110 |
Why?
|
| Carbon Tetrachloride | 4 | 2001 | 8 | 0.100 |
Why?
|
| Mannose-Binding Lectins | 1 | 2012 | 4 | 0.100 |
Why?
|
| Acetone | 1 | 2012 | 6 | 0.100 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 513 | 0.090 |
Why?
|
| Fatty Liver | 2 | 2012 | 77 | 0.090 |
Why?
|
| Lectins, C-Type | 1 | 2012 | 44 | 0.090 |
Why?
|
| Transcription Factor RelA | 1 | 2012 | 22 | 0.090 |
Why?
|
| p120 GTPase Activating Protein | 1 | 2012 | 2 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 114 | 0.090 |
Why?
|
| Testosterone | 1 | 2012 | 74 | 0.090 |
Why?
|
| Trans-Activators | 2 | 2004 | 118 | 0.090 |
Why?
|
| Cell Line | 3 | 2018 | 700 | 0.090 |
Why?
|
| DNA-Binding Proteins | 3 | 2005 | 490 | 0.090 |
Why?
|
| Dexamethasone | 2 | 2001 | 63 | 0.080 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2001 | 25 | 0.080 |
Why?
|
| Disease Progression | 1 | 2012 | 477 | 0.080 |
Why?
|
| Social Change | 1 | 2010 | 4 | 0.080 |
Why?
|
| Administrative Personnel | 1 | 2010 | 7 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2004 | 328 | 0.080 |
Why?
|
| Faculty | 1 | 2010 | 62 | 0.080 |
Why?
|
| Interleukin-1 | 3 | 2004 | 23 | 0.080 |
Why?
|
| Adult | 2 | 2020 | 8024 | 0.070 |
Why?
|
| Middle Aged | 1 | 2020 | 7414 | 0.070 |
Why?
|
| Rats, Long-Evans | 2 | 2005 | 35 | 0.070 |
Why?
|
| Cystitis | 1 | 2007 | 11 | 0.070 |
Why?
|
| BCG Vaccine | 1 | 2007 | 14 | 0.070 |
Why?
|
| Granulation Tissue | 1 | 2007 | 7 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2007 | 247 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor | 3 | 2001 | 18 | 0.070 |
Why?
|
| Interleukin-17 | 1 | 2007 | 52 | 0.060 |
Why?
|
| Melanoma, Experimental | 2 | 2000 | 31 | 0.060 |
Why?
|
| DNA Primers | 2 | 2004 | 147 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 2007 | 119 | 0.060 |
Why?
|
| Janus Kinase 1 | 1 | 2006 | 4 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 86 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 97 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 12 | 0.060 |
Why?
|
| Neutrophil Infiltration | 1 | 2004 | 19 | 0.060 |
Why?
|
| Organoids | 1 | 2024 | 23 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 1996 | 416 | 0.050 |
Why?
|
| Heart | 1 | 2005 | 232 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 1998 | 677 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2024 | 118 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 88 | 0.050 |
Why?
|
| Transcription Factor AP-1 | 2 | 2000 | 26 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 140 | 0.050 |
Why?
|
| Lung Neoplasms | 2 | 2000 | 360 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 157 | 0.050 |
Why?
|
| Mice, Inbred C3H | 2 | 2000 | 74 | 0.050 |
Why?
|
| Matrix Metalloproteinase 10 | 1 | 2001 | 1 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2001 | 60 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 2001 | 40 | 0.040 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2000 | 4 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2001 | 78 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2000 | 115 | 0.040 |
Why?
|
| Hepatectomy | 1 | 2000 | 26 | 0.040 |
Why?
|
| Cell Separation | 1 | 2000 | 57 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2000 | 124 | 0.040 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 1999 | 5 | 0.040 |
Why?
|
| Spleen | 3 | 1997 | 113 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2001 | 265 | 0.040 |
Why?
|
| Toxicity Tests | 1 | 2018 | 11 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2018 | 29 | 0.040 |
Why?
|
| Mercury | 1 | 2018 | 12 | 0.040 |
Why?
|
| Vanadium Compounds | 1 | 1998 | 1 | 0.040 |
Why?
|
| Cadmium Chloride | 1 | 1998 | 2 | 0.040 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2018 | 54 | 0.040 |
Why?
|
| Metals | 1 | 2018 | 41 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 1998 | 314 | 0.040 |
Why?
|
| Hepatitis, Animal | 1 | 1997 | 1 | 0.030 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1997 | 9 | 0.030 |
Why?
|
| Physical Conditioning, Animal | 2 | 1997 | 46 | 0.030 |
Why?
|
| Water | 1 | 2018 | 135 | 0.030 |
Why?
|
| Carbon | 1 | 2018 | 107 | 0.030 |
Why?
|
| Antibodies | 1 | 1997 | 125 | 0.030 |
Why?
|
| Physical Exertion | 1 | 1997 | 104 | 0.030 |
Why?
|
| Genes, Immediate-Early | 1 | 1997 | 5 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 1998 | 169 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 1997 | 96 | 0.030 |
Why?
|
| Genes, myc | 1 | 1996 | 9 | 0.030 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1996 | 7 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1996 | 13 | 0.030 |
Why?
|
| Cell Count | 1 | 1996 | 86 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 1995 | 52 | 0.030 |
Why?
|
| Lymphocyte Cooperation | 1 | 1994 | 1 | 0.030 |
Why?
|
| Cell Survival | 1 | 1996 | 419 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1994 | 612 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 1994 | 285 | 0.020 |
Why?
|
| Apoptosis | 1 | 1996 | 780 | 0.020 |
Why?
|
| Lipopolysaccharides | 2 | 2007 | 157 | 0.020 |
Why?
|
| United States | 1 | 2018 | 2222 | 0.020 |
Why?
|
| Alanine Transaminase | 2 | 2001 | 27 | 0.020 |
Why?
|
| Schools, Pharmacy | 1 | 2010 | 32 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 2 | 2001 | 20 | 0.020 |
Why?
|
| Leadership | 1 | 2010 | 55 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2000 | 19 | 0.020 |
Why?
|
| Rats, Inbred F344 | 2 | 1998 | 174 | 0.020 |
Why?
|
| DNA | 2 | 2001 | 377 | 0.020 |
Why?
|
| Administration, Intravesical | 1 | 2007 | 16 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2007 | 29 | 0.020 |
Why?
|
| Granuloma | 1 | 2007 | 18 | 0.020 |
Why?
|
| Organ Size | 2 | 1999 | 88 | 0.020 |
Why?
|
| Rabbits | 2 | 1997 | 277 | 0.020 |
Why?
|
| Body Weight | 2 | 1999 | 250 | 0.020 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2005 | 7 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2005 | 8 | 0.010 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2005 | 12 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 2005 | 19 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 2005 | 22 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2005 | 122 | 0.010 |
Why?
|
| Physical Endurance | 2 | 1997 | 91 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2005 | 45 | 0.010 |
Why?
|
| Myocardium | 1 | 2005 | 196 | 0.010 |
Why?
|
| Leukocyte Count | 2 | 1994 | 25 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 2001 | 20 | 0.010 |
Why?
|
| Fibrillar Collagens | 1 | 2001 | 7 | 0.010 |
Why?
|
| Peroxidase | 1 | 2001 | 39 | 0.010 |
Why?
|
| Keratins | 1 | 2001 | 10 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2005 | 523 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2001 | 59 | 0.010 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2001 | 12 | 0.010 |
Why?
|
| Random Allocation | 1 | 2001 | 151 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2001 | 26 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2001 | 267 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 257 | 0.010 |
Why?
|
| RNA | 1 | 2001 | 111 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2001 | 191 | 0.010 |
Why?
|
| Central Nervous System Depressants | 1 | 2000 | 13 | 0.010 |
Why?
|
| Necrosis | 1 | 2000 | 85 | 0.010 |
Why?
|
| Protein Binding | 1 | 2001 | 667 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1999 | 119 | 0.010 |
Why?
|
| Leukocytes | 1 | 1999 | 72 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2001 | 427 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 1998 | 45 | 0.010 |
Why?
|
| Chemotaxis | 1 | 1998 | 28 | 0.010 |
Why?
|
| Monokines | 1 | 1997 | 1 | 0.010 |
Why?
|
| Chemotactic Factors | 1 | 1997 | 7 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1997 | 46 | 0.010 |
Why?
|
| Chemokine CXCL2 | 1 | 1997 | 6 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 1998 | 145 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1999 | 254 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1997 | 59 | 0.010 |
Why?
|
| Time Factors | 1 | 2001 | 1613 | 0.010 |
Why?
|
| Proto-Oncogenes | 1 | 1997 | 15 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1997 | 90 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 1998 | 292 | 0.010 |
Why?
|
| Antioxidants | 1 | 1998 | 224 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1997 | 274 | 0.010 |
Why?
|
| Mutation | 1 | 2000 | 867 | 0.010 |
Why?
|
| Energy Intake | 1 | 1994 | 69 | 0.010 |
Why?
|
| Corticosterone | 1 | 1994 | 35 | 0.010 |
Why?
|
| Eating | 1 | 1994 | 71 | 0.010 |
Why?
|
| Poly I-C | 1 | 1993 | 13 | 0.010 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1993 | 28 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1993 | 60 | 0.010 |
Why?
|
| Nutritional Status | 1 | 1993 | 80 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1993 | 607 | 0.000 |
Why?
|